http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 29 Jun 2026 09:04:42 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Intl+Ratings/Medexus+Pharma+%28MDP%3ACN%29+%28PDDPF%29+PT+Raised+to+Cdn%246.50+at+Canaccord/26703013.html Canaccord analyst Tania Armstrong-Whitworth raised the price target on Medexus Pharma (MDP:CN) (OTC: PDDPF) to Cdn$6.50 (from Cdn$6.00) while maintaining a Buy rating. http://www.streetinsider.com/Intl+Ratings/Medexus+Pharma+%28MDP%3ACN%29+%28PDDPF%29+PT+Raised+to+Cdn%246.50+at+Canaccord/26703013.html Mon, 29 Jun 2026 09:04:42 -0400 PDDPF http://www.streetinsider.com/Analyst+PT+Change/Medexus+Pharma+%28MDP%3ACN%29+%28PDDPF%29+PT+Raised+to+Cdn%246.50+at+Canaccord/26703013.html Canaccord analyst Tania Armstrong-Whitworth raised the price target on Medexus Pharma (MDP:CN) (OTC: PDDPF) to Cdn$6.50 (from Cdn$6.00) while maintaining a Buy rating. http://www.streetinsider.com/Analyst+PT+Change/Medexus+Pharma+%28MDP%3ACN%29+%28PDDPF%29+PT+Raised+to+Cdn%246.50+at+Canaccord/26703013.html Mon, 29 Jun 2026 09:04:42 -0400 PDDPF http://www.streetinsider.com/Intl+Ratings/Medexus+Pharma+%28MDP%3ACN%29+%28PDDPF%29+PT+Raised+to+Cdn%246.50+at+Canaccord/26703013.html Canaccord analyst Tania Armstrong-Whitworth raised the price target on Medexus Pharma (MDP:CN) (OTC: PDDPF) to Cdn$6.50 (from Cdn$6.00) while maintaining a Buy rating. http://www.streetinsider.com/Intl+Ratings/Medexus+Pharma+%28MDP%3ACN%29+%28PDDPF%29+PT+Raised+to+Cdn%246.50+at+Canaccord/26703013.html Mon, 29 Jun 2026 09:04:42 -0400 PDDPF http://www.streetinsider.com/Analyst+PT+Change/Medexus+Pharma+%28MDP%3ACN%29+%28PDDPF%29+PT+Raised+to+Cdn%246.50+at+Canaccord/26703013.html Canaccord analyst Tania Armstrong-Whitworth raised the price target on Medexus Pharma (MDP:CN) (OTC: PDDPF) to Cdn$6.50 (from Cdn$6.00) while maintaining a Buy rating. http://www.streetinsider.com/Analyst+PT+Change/Medexus+Pharma+%28MDP%3ACN%29+%28PDDPF%29+PT+Raised+to+Cdn%246.50+at+Canaccord/26703013.html Mon, 29 Jun 2026 09:04:42 -0400 PDDPF http://www.streetinsider.com/Intl+Ratings/Canaccord+Resumes+Medexus+Pharma+%28MDP%3ACN%29+%28PDDPF%29+at+Buy/26544815.html <p>Canaccord analyst Tania Armstrong-Whitworth resumes coverage on Medexus Pharma (MDP:CN) (OTC: PDDPF) with a Buy rating and a price target of Cdn$6.00.</p><p>The analyst comments: “The 2018 merger of Medexus, medac US, and Pediapharm created an at-scale, North American specialty pharmaceutical platform focused on the areas of hematology and hemato-oncology, rheumatology, and allergy. Today, MDP has a combined 14 brands across the US and Canada that generated ~US$100.0M of revenue in C2025. Approved by the FDA and launched in early 2025, management believes GRAFAPEX has the potential to become the standard-of-care allo-HSCT conditioning regimen in North America, reaching peak sales of http://www.streetinsider.com/Intl+Ratings/Canaccord+Resumes+Medexus+Pharma+%28MDP%3ACN%29+%28PDDPF%29+at+Buy/26544815.html Tue, 26 May 2026 04:03:54 -0400 PDDPF http://www.streetinsider.com/New+Coverage/Canaccord+Resumes+Medexus+Pharma+%28MDP%3ACN%29+%28PDDPF%29+at+Buy/26544815.html <p>Canaccord analyst Tania Armstrong-Whitworth resumes coverage on Medexus Pharma (MDP:CN) (OTC: PDDPF) with a Buy rating and a price target of Cdn$6.00.</p><p>The analyst comments: “The 2018 merger of Medexus, medac US, and Pediapharm created an at-scale, North American specialty pharmaceutical platform focused on the areas of hematology and hemato-oncology, rheumatology, and allergy. Today, MDP has a combined 14 brands across the US and Canada that generated ~US$100.0M of revenue in C2025. Approved by the FDA and launched in early 2025, management believes GRAFAPEX has the potential to become the standard-of-care allo-HSCT conditioning regimen in North America, reaching peak sales of http://www.streetinsider.com/New+Coverage/Canaccord+Resumes+Medexus+Pharma+%28MDP%3ACN%29+%28PDDPF%29+at+Buy/26544815.html Tue, 26 May 2026 04:03:54 -0400 PDDPF http://www.streetinsider.com/Analyst+Comments/Canaccord+Resumes+Medexus+Pharma+%28MDP%3ACN%29+%28PDDPF%29+at+Buy/26544815.html <p>Canaccord analyst Tania Armstrong-Whitworth resumes coverage on Medexus Pharma (MDP:CN) (OTC: PDDPF) with a Buy rating and a price target of Cdn$6.00.</p><p>The analyst comments: “The 2018 merger of Medexus, medac US, and Pediapharm created an at-scale, North American specialty pharmaceutical platform focused on the areas of hematology and hemato-oncology, rheumatology, and allergy. Today, MDP has a combined 14 brands across the US and Canada that generated ~US$100.0M of revenue in C2025. Approved by the FDA and launched in early 2025, management believes GRAFAPEX has the potential to become the standard-of-care allo-HSCT conditioning regimen in North America, reaching peak sales of http://www.streetinsider.com/Analyst+Comments/Canaccord+Resumes+Medexus+Pharma+%28MDP%3ACN%29+%28PDDPF%29+at+Buy/26544815.html Tue, 26 May 2026 04:03:54 -0400 PDDPF http://www.streetinsider.com/Intl+Ratings/Canaccord+Resumes+Medexus+Pharma+%28MDP%3ACN%29+%28PDDPF%29+at+Buy/26544815.html <p>Canaccord analyst Tania Armstrong-Whitworth resumes coverage on Medexus Pharma (MDP:CN) (OTC: PDDPF) with a Buy rating and a price target of Cdn$6.00.</p><p>The analyst comments: “The 2018 merger of Medexus, medac US, and Pediapharm created an at-scale, North American specialty pharmaceutical platform focused on the areas of hematology and hemato-oncology, rheumatology, and allergy. Today, MDP has a combined 14 brands across the US and Canada that generated ~US$100.0M of revenue in C2025. Approved by the FDA and launched in early 2025, management believes GRAFAPEX has the potential to become the standard-of-care allo-HSCT conditioning regimen in North America, reaching peak sales of http://www.streetinsider.com/Intl+Ratings/Canaccord+Resumes+Medexus+Pharma+%28MDP%3ACN%29+%28PDDPF%29+at+Buy/26544815.html Tue, 26 May 2026 04:03:54 -0400 PDDPF http://www.streetinsider.com/New+Coverage/Canaccord+Resumes+Medexus+Pharma+%28MDP%3ACN%29+%28PDDPF%29+at+Buy/26544815.html <p>Canaccord analyst Tania Armstrong-Whitworth resumes coverage on Medexus Pharma (MDP:CN) (OTC: PDDPF) with a Buy rating and a price target of Cdn$6.00.</p><p>The analyst comments: “The 2018 merger of Medexus, medac US, and Pediapharm created an at-scale, North American specialty pharmaceutical platform focused on the areas of hematology and hemato-oncology, rheumatology, and allergy. Today, MDP has a combined 14 brands across the US and Canada that generated ~US$100.0M of revenue in C2025. Approved by the FDA and launched in early 2025, management believes GRAFAPEX has the potential to become the standard-of-care allo-HSCT conditioning regimen in North America, reaching peak sales of http://www.streetinsider.com/New+Coverage/Canaccord+Resumes+Medexus+Pharma+%28MDP%3ACN%29+%28PDDPF%29+at+Buy/26544815.html Tue, 26 May 2026 04:03:54 -0400 PDDPF http://www.streetinsider.com/Analyst+Comments/Canaccord+Resumes+Medexus+Pharma+%28MDP%3ACN%29+%28PDDPF%29+at+Buy/26544815.html <p>Canaccord analyst Tania Armstrong-Whitworth resumes coverage on Medexus Pharma (MDP:CN) (OTC: PDDPF) with a Buy rating and a price target of Cdn$6.00.</p><p>The analyst comments: “The 2018 merger of Medexus, medac US, and Pediapharm created an at-scale, North American specialty pharmaceutical platform focused on the areas of hematology and hemato-oncology, rheumatology, and allergy. Today, MDP has a combined 14 brands across the US and Canada that generated ~US$100.0M of revenue in C2025. Approved by the FDA and launched in early 2025, management believes GRAFAPEX has the potential to become the standard-of-care allo-HSCT conditioning regimen in North America, reaching peak sales of http://www.streetinsider.com/Analyst+Comments/Canaccord+Resumes+Medexus+Pharma+%28MDP%3ACN%29+%28PDDPF%29+at+Buy/26544815.html Tue, 26 May 2026 04:03:54 -0400 PDDPF http://www.streetinsider.com/Intl+Ratings/Raymond+James+Reiterates+Strong+Buy+Rating+on+Medexus+Pharma+%28MDP%3ACN%29+%28PDDPF%29/24992230.html <p>Raymond James analyst Michael Freeman reiterated a Strong Buy rating and Cdn$8.00 price target on Medexus Pharma (MDP:CN) (OTC: PDDPF).</p> http://www.streetinsider.com/Intl+Ratings/Raymond+James+Reiterates+Strong+Buy+Rating+on+Medexus+Pharma+%28MDP%3ACN%29+%28PDDPF%29/24992230.html Sat, 28 Jun 2025 00:54:48 -0400 PDDPF http://www.streetinsider.com/Intl+Ratings/Raymond+James+Reiterates+Strong+Buy+Rating+on+Medexus+Pharma+%28MDP%3ACN%29+%28PDDPF%29/24992230.html <p>Raymond James analyst Michael Freeman reiterated a Strong Buy rating and Cdn$8.00 price target on Medexus Pharma (MDP:CN) (OTC: PDDPF).</p> http://www.streetinsider.com/Intl+Ratings/Raymond+James+Reiterates+Strong+Buy+Rating+on+Medexus+Pharma+%28MDP%3ACN%29+%28PDDPF%29/24992230.html Sat, 28 Jun 2025 00:54:48 -0400 PDDPF http://www.streetinsider.com/Intl+Ratings/Canaccord+Genuity+Reiterates+Spec.+Buy+Rating+on+Medexus+Pharma+%28MDP%3ACN%29+%28PDDPF%29/24988432.html <p>Canaccord Genuity analyst Tania Armstrong-Whitworth reiterated a Spec. Buy rating and Cdn$6.00 price target on Medexus Pharma (MDP:CN) (OTC: PDDPF).</p> http://www.streetinsider.com/Intl+Ratings/Canaccord+Genuity+Reiterates+Spec.+Buy+Rating+on+Medexus+Pharma+%28MDP%3ACN%29+%28PDDPF%29/24988432.html Fri, 27 Jun 2025 11:33:48 -0400 PDDPF http://www.streetinsider.com/Intl+Ratings/Canaccord+Genuity+Reiterates+Spec.+Buy+Rating+on+Medexus+Pharma+%28MDP%3ACN%29+%28PDDPF%29/24988432.html <p>Canaccord Genuity analyst Tania Armstrong-Whitworth reiterated a Spec. Buy rating and Cdn$6.00 price target on Medexus Pharma (MDP:CN) (OTC: PDDPF).</p> http://www.streetinsider.com/Intl+Ratings/Canaccord+Genuity+Reiterates+Spec.+Buy+Rating+on+Medexus+Pharma+%28MDP%3ACN%29+%28PDDPF%29/24988432.html Fri, 27 Jun 2025 11:33:48 -0400 PDDPF http://www.streetinsider.com/Analyst+PT+Change/Stifel+Canada+Downgrades+Medexus+Pharma+%28MDP%3ACN%29+%28PDDPF%29+to+Hold/24312823.html <p>Stifel Canada analyst Justin Keywood downgraded Medexus Pharma (MDP:CN) (OTC: PDDPF) from Buy to Hold with a price target of Cdn$3.45 (from Cdn$6.00).</p><p>The analyst comments: "Medexus FQ3 results showed well (detailed below), consistent with pre-released financials last month that were well ahead of initial estimates. MDP is up ~40% in LTM and peaked at ~$5.00/share, vs. ~$2.00 in Nov., following the FDA approval of GRAFAPEX (treosulfan), an important treatment for allogeneic hematopoietic stem cell transplantation. However, initial pricing assumptions of US$25k/treatment appears optimistic, including a recent pharmacoeconomic review. The pricing would also be multiple times higher than in Canada and http://www.streetinsider.com/Analyst+PT+Change/Stifel+Canada+Downgrades+Medexus+Pharma+%28MDP%3ACN%29+%28PDDPF%29+to+Hold/24312823.html Fri, 07 Feb 2025 08:19:53 -0400 PDDPF http://www.streetinsider.com/Downgrades/Stifel+Canada+Downgrades+Medexus+Pharma+%28MDP%3ACN%29+%28PDDPF%29+to+Hold/24312823.html <p>Stifel Canada analyst Justin Keywood downgraded Medexus Pharma (MDP:CN) (OTC: PDDPF) from Buy to Hold with a price target of Cdn$3.45 (from Cdn$6.00).</p><p>The analyst comments: "Medexus FQ3 results showed well (detailed below), consistent with pre-released financials last month that were well ahead of initial estimates. MDP is up ~40% in LTM and peaked at ~$5.00/share, vs. ~$2.00 in Nov., following the FDA approval of GRAFAPEX (treosulfan), an important treatment for allogeneic hematopoietic stem cell transplantation. However, initial pricing assumptions of US$25k/treatment appears optimistic, including a recent pharmacoeconomic review. The pricing would also be multiple times higher than in Canada and http://www.streetinsider.com/Downgrades/Stifel+Canada+Downgrades+Medexus+Pharma+%28MDP%3ACN%29+%28PDDPF%29+to+Hold/24312823.html Fri, 07 Feb 2025 08:19:53 -0400 PDDPF http://www.streetinsider.com/Intl+Ratings/Stifel+Canada+Downgrades+Medexus+Pharma+%28MDP%3ACN%29+%28PDDPF%29+to+Hold/24312823.html <p>Stifel Canada analyst Justin Keywood downgraded Medexus Pharma (MDP:CN) (OTC: PDDPF) from Buy to Hold with a price target of Cdn$3.45 (from Cdn$6.00).</p><p>The analyst comments: "Medexus FQ3 results showed well (detailed below), consistent with pre-released financials last month that were well ahead of initial estimates. MDP is up ~40% in LTM and peaked at ~$5.00/share, vs. ~$2.00 in Nov., following the FDA approval of GRAFAPEX (treosulfan), an important treatment for allogeneic hematopoietic stem cell transplantation. However, initial pricing assumptions of US$25k/treatment appears optimistic, including a recent pharmacoeconomic review. The pricing would also be multiple times higher than in Canada and http://www.streetinsider.com/Intl+Ratings/Stifel+Canada+Downgrades+Medexus+Pharma+%28MDP%3ACN%29+%28PDDPF%29+to+Hold/24312823.html Fri, 07 Feb 2025 08:19:53 -0400 PDDPF http://www.streetinsider.com/Analyst+Comments/Stifel+Canada+Downgrades+Medexus+Pharma+%28MDP%3ACN%29+%28PDDPF%29+to+Hold/24312823.html <p>Stifel Canada analyst Justin Keywood downgraded Medexus Pharma (MDP:CN) (OTC: PDDPF) from Buy to Hold with a price target of Cdn$3.45 (from Cdn$6.00).</p><p>The analyst comments: "Medexus FQ3 results showed well (detailed below), consistent with pre-released financials last month that were well ahead of initial estimates. MDP is up ~40% in LTM and peaked at ~$5.00/share, vs. ~$2.00 in Nov., following the FDA approval of GRAFAPEX (treosulfan), an important treatment for allogeneic hematopoietic stem cell transplantation. However, initial pricing assumptions of US$25k/treatment appears optimistic, including a recent pharmacoeconomic review. The pricing would also be multiple times higher than in Canada and http://www.streetinsider.com/Analyst+Comments/Stifel+Canada+Downgrades+Medexus+Pharma+%28MDP%3ACN%29+%28PDDPF%29+to+Hold/24312823.html Fri, 07 Feb 2025 08:19:53 -0400 PDDPF http://www.streetinsider.com/Analyst+PT+Change/Stifel+Canada+Downgrades+Medexus+Pharma+%28MDP%3ACN%29+%28PDDPF%29+to+Hold/24312823.html <p>Stifel Canada analyst Justin Keywood downgraded Medexus Pharma (MDP:CN) (OTC: PDDPF) from Buy to Hold with a price target of Cdn$3.45 (from Cdn$6.00).</p><p>The analyst comments: "Medexus FQ3 results showed well (detailed below), consistent with pre-released financials last month that were well ahead of initial estimates. MDP is up ~40% in LTM and peaked at ~$5.00/share, vs. ~$2.00 in Nov., following the FDA approval of GRAFAPEX (treosulfan), an important treatment for allogeneic hematopoietic stem cell transplantation. However, initial pricing assumptions of US$25k/treatment appears optimistic, including a recent pharmacoeconomic review. The pricing would also be multiple times higher than in Canada and http://www.streetinsider.com/Analyst+PT+Change/Stifel+Canada+Downgrades+Medexus+Pharma+%28MDP%3ACN%29+%28PDDPF%29+to+Hold/24312823.html Fri, 07 Feb 2025 08:19:53 -0400 PDDPF http://www.streetinsider.com/Downgrades/Stifel+Canada+Downgrades+Medexus+Pharma+%28MDP%3ACN%29+%28PDDPF%29+to+Hold/24312823.html <p>Stifel Canada analyst Justin Keywood downgraded Medexus Pharma (MDP:CN) (OTC: PDDPF) from Buy to Hold with a price target of Cdn$3.45 (from Cdn$6.00).</p><p>The analyst comments: "Medexus FQ3 results showed well (detailed below), consistent with pre-released financials last month that were well ahead of initial estimates. MDP is up ~40% in LTM and peaked at ~$5.00/share, vs. ~$2.00 in Nov., following the FDA approval of GRAFAPEX (treosulfan), an important treatment for allogeneic hematopoietic stem cell transplantation. However, initial pricing assumptions of US$25k/treatment appears optimistic, including a recent pharmacoeconomic review. The pricing would also be multiple times higher than in Canada and http://www.streetinsider.com/Downgrades/Stifel+Canada+Downgrades+Medexus+Pharma+%28MDP%3ACN%29+%28PDDPF%29+to+Hold/24312823.html Fri, 07 Feb 2025 08:19:53 -0400 PDDPF http://www.streetinsider.com/Intl+Ratings/Stifel+Canada+Downgrades+Medexus+Pharma+%28MDP%3ACN%29+%28PDDPF%29+to+Hold/24312823.html <p>Stifel Canada analyst Justin Keywood downgraded Medexus Pharma (MDP:CN) (OTC: PDDPF) from Buy to Hold with a price target of Cdn$3.45 (from Cdn$6.00).</p><p>The analyst comments: "Medexus FQ3 results showed well (detailed below), consistent with pre-released financials last month that were well ahead of initial estimates. MDP is up ~40% in LTM and peaked at ~$5.00/share, vs. ~$2.00 in Nov., following the FDA approval of GRAFAPEX (treosulfan), an important treatment for allogeneic hematopoietic stem cell transplantation. However, initial pricing assumptions of US$25k/treatment appears optimistic, including a recent pharmacoeconomic review. The pricing would also be multiple times higher than in Canada and http://www.streetinsider.com/Intl+Ratings/Stifel+Canada+Downgrades+Medexus+Pharma+%28MDP%3ACN%29+%28PDDPF%29+to+Hold/24312823.html Fri, 07 Feb 2025 08:19:53 -0400 PDDPF http://www.streetinsider.com/Analyst+Comments/Stifel+Canada+Downgrades+Medexus+Pharma+%28MDP%3ACN%29+%28PDDPF%29+to+Hold/24312823.html <p>Stifel Canada analyst Justin Keywood downgraded Medexus Pharma (MDP:CN) (OTC: PDDPF) from Buy to Hold with a price target of Cdn$3.45 (from Cdn$6.00).</p><p>The analyst comments: "Medexus FQ3 results showed well (detailed below), consistent with pre-released financials last month that were well ahead of initial estimates. MDP is up ~40% in LTM and peaked at ~$5.00/share, vs. ~$2.00 in Nov., following the FDA approval of GRAFAPEX (treosulfan), an important treatment for allogeneic hematopoietic stem cell transplantation. However, initial pricing assumptions of US$25k/treatment appears optimistic, including a recent pharmacoeconomic review. The pricing would also be multiple times higher than in Canada and http://www.streetinsider.com/Analyst+Comments/Stifel+Canada+Downgrades+Medexus+Pharma+%28MDP%3ACN%29+%28PDDPF%29+to+Hold/24312823.html Fri, 07 Feb 2025 08:19:53 -0400 PDDPF http://www.streetinsider.com/Intl+Ratings/Medexus+Pharma+%28MDP%3ACN%29+%28PDDPF%29+PT+Raised+to+Cdn%248+at+Raymond+James/24288959.html Raymond James analyst Michael Freeman raised the price target on Medexus Pharma (MDP:CN) (OTC: PDDPF) to Cdn$8.00 (from Cdn$4.00) while maintaining a Strong Buy rating. http://www.streetinsider.com/Intl+Ratings/Medexus+Pharma+%28MDP%3ACN%29+%28PDDPF%29+PT+Raised+to+Cdn%248+at+Raymond+James/24288959.html Tue, 04 Feb 2025 02:44:14 -0400 PDDPF http://www.streetinsider.com/Analyst+PT+Change/Medexus+Pharma+%28MDP%3ACN%29+%28PDDPF%29+PT+Raised+to+Cdn%248+at+Raymond+James/24288959.html Raymond James analyst Michael Freeman raised the price target on Medexus Pharma (MDP:CN) (OTC: PDDPF) to Cdn$8.00 (from Cdn$4.00) while maintaining a Strong Buy rating. http://www.streetinsider.com/Analyst+PT+Change/Medexus+Pharma+%28MDP%3ACN%29+%28PDDPF%29+PT+Raised+to+Cdn%248+at+Raymond+James/24288959.html Tue, 04 Feb 2025 02:44:14 -0400 PDDPF http://www.streetinsider.com/Intl+Ratings/Medexus+Pharma+%28MDP%3ACN%29+%28PDDPF%29+PT+Raised+to+Cdn%248+at+Raymond+James/24288959.html Raymond James analyst Michael Freeman raised the price target on Medexus Pharma (MDP:CN) (OTC: PDDPF) to Cdn$8.00 (from Cdn$4.00) while maintaining a Strong Buy rating. http://www.streetinsider.com/Intl+Ratings/Medexus+Pharma+%28MDP%3ACN%29+%28PDDPF%29+PT+Raised+to+Cdn%248+at+Raymond+James/24288959.html Tue, 04 Feb 2025 02:44:14 -0400 PDDPF